Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems

Vaccine

Volumn 17, Issue 15-16, 1999, Pages 2009-2019

  Elliott, Suzanne L ^a   Pye, Stephanie ^a   Le, Thuy ^a   Mateo, Luis ^a   Cox, John ^b   MacDonald, Lisa ^b   Scalzo, Anthony A ^c   Forbes, Cathy A ^c   Suhrbier, Andreas ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b CSL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cytotoxic T lymphocyte; Peptide; Vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FLUVAX; GLUTAMIC ACID; SYNTHETIC PEPTIDE; TUBERCULIN; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL INTERACTION; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EPITOPE MAPPING; HUMAN; HUMAN CELL; HUMAN TISSUE; OLIGOMERIZATION; PEPTIDE ANALYSIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; EMULSIONS; EPITOPES; HERPESVIRIDAE INFECTIONS; HYDROGEN-ION CONCENTRATION; IMMUNOLOGIC MEMORY; MAJOR HISTOCOMPATIBILITY COMPLEX; MANNITOL; METHIONINE; MICE; MICE, INBRED STRAINS; OLEIC ACIDS; OXIDATION-REDUCTION; PEPTIDES; PYRROLIDONECARBOXYLIC ACID; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; TETANUS TOXOID; VACCINES, SYNTHETIC;

EID: 0033537857     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00468-X     Document Type: Article

References (47)

1. Moss D.J., Schmidt C., Elliott S., Suhrbier A., Burrows S., Khanna R. Strategies involved in developing an effective vaccine for EBV-associated diseases. Adv. Cancer Res. 69:1996;213-245.
2. Rowland-Jones S., Tan R., McMichael A. Role of cellular immunity in protection against HIV infection. Adv. Immunol. 65:1997;277-346.
3. Sirard J.C., Fayolle C., de Chastellier C., Mock M., Leclerc C., Berche Intracytoplasmic delivery of listeriolysin O by a vaccinal strain of Bacillus anthracis induces CD8-mediated protection against Listeria monocytogenes. J. Immunol. 159:1997;4435-4443.
4. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J., Wunderlich J.R., Parkhurst M.R., Kawakami Y., Seipp C.A., Einhorn J.H., White D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:1998;321-327.
5. Boyer J.D., Ugen K.E., Wang B., Agadjanyan M., Gilbert L., Bagarazzi M.L., Chattergoon M., Frost P., Javadian A., Williams W.V., Refaeli Y., Ciccarelli R.B., McCallus C., Coney L., Weiner D.B. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med. 3:1997;526-532.
6. Lubeck M.D., Natuk R., Myagkikh M., Kalyan N., Aldrich K., Sinangil F., Alipanah S., Murthy S.C., Chanda P.K., Nigida S.M. Jr., Markham P.D., Zolla-Pazner S., Steimer K., Wade M. Jr., Reitz M.S., Arthur L.O., Mizutani S., Davis A., Hung P.P., Gallo R.C., Eichberg J., Robert-Guroff M. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat. Med. 3:1997;651-658.
7. Clements-Mann M.L., Weinhold K., Matthews T.J., Graham B.S., Gorse G.J., Keefer M.C., McElrath M.J., Hsieh R.H., Mestecky J., Zolla-Pazner S., Mascola J., Schwartz D., Siliciano R., Corey L., Wright P.F., Belshe R., Dolin R., Jackson S., Xu S., Fast P., Walker M.C., Stablein D., Excler J.L., Tartaglia J., Paoletti E. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J. Infect. Dis. 177:1998;1230-1230.
8. Yasutomi Y., Palker T.J., Gardner M.B., Haynes B.F., Letvin N.L. Synthetic peptide in mineral oil adjuvant elicits simian immunodeficiency virus-specific CD8+ cytotoxic T-lymphocytes in rhesus monkeys. J. Immunol. 151:1993;5096-5105.
9. Livingston B.D., Crimi C., Grey H., Ishioka G., Chisari F.V., Fikes J., Grey H., Chesnut R.W., Sette A. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J. Immunol. 159:1997;1383-1392.
10. Gjertsen M.K., Bjorheim J., Saeterdal I., Myklebust J., Gaudernack G. Cytotoxic CD4+ and CD8+ T-lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int. J. Cancer. 72:1997;784-790.
11. Jager E., Ringhoffer M., Dienes H.P., Arand M., Karbach J., Jager D., Ilsemann C., Hagedorn M., Oesch M.F., Knuth A. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer. 67:1996;54-62.
12. Goydos J.S., Elder E., Whiteside T.L., Finn O.J., Lotze M.T. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63:1996;298-304.
13. Hamajima K., Fukushima J., Bukawa H., Kaneko T., Tsuji T., Asakura Y., Sasaki S., Xin K.Q., Okuda K. Strong augment effect of IL-12 expression plasmid on the induction of HIV-specific cytotoxic T-lymphocyte activity by a peptide vaccine candidate. Clin. Immunol. Immunopathol. 83:1997;179-184.
14. Gulukota K., DeLisi C. HLA allele selection for designing peptide vaccines. Genet. Anal. 13:1996;81-86.
15. Mortara L., Letourneur F., Gras-Masse H., Venet A., Guillet J.G., Bourgault-Villada I. Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine. J. Virol. 72:1998;1403-1410.
16. Chen W., Ede N.J., Jackson D.C., McCluskey J., Purcell A.W. CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. J. Immunol. 157:1996;1000-1005.
17. Fernan A., Burrows S.R., Moss D.J., Saul A., Suhrbier A. Inhibition of HLA B8-restricted recognition by unrelated peptides: evidence for allosteric inhibition. Immunol. Lett. 30:1991;339-344.
18. Van Waes C., Monach P.A., Urban J.L., Wortzel R.D., Schreiber H. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T-cells in vitro. Tissue Antigens. 47:1996;399-407.
19. Eberl G., Kessler B., Eberl L.P., Brunda M.J., Valmori D., Corradin G. Immunodominance of cytotoxic T-lymphocyte epitopes co-injected in vivo and modulation by interleukin-12. Eur. J. Immunol. 26:1996;2709-2716.
20. Adorini L., Nagy Z.A. Peptide competition for antigen presentation. Immunol. Today. 11:1990;21-24.
21. Scalzo A.A., Elliott S.L., Cox J., Gardner J., Moss D.J., Suhrbier A. Induction of protective cytotoxic T-cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J. Virol. 69:1995;1306-1309.
22. Moss D.J., Suhrbier A., Elliott S.L. Candidate vaccines for Epstein-Barr virus. Br. Med. J. 317(7156):1998;423-424.
23. Lawrence G.W., Saul A., Giddy A.J., Kemp R., Pye D. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine. 15:1997;176-178.
24. Elliot T., Smith M., Driscoll P., McMichael A. Peptide selection by class I molecules of the major histocompatibility complex. Curr. Biol. 3:1993;854-858.
25. Schmidt W., Buschle M., Zauner W., Kirlappos H., Mechtler K., Trska B., Birnstiel M.L. Cell-free tumor antigen peptide-based cancer vaccines. Proc. Natl. Acad. Sci. USA. 94:1997;3262-3267.
26. Aggeli A., Bell M., Boden N., Keen J.N., Knowles P.F., McLeish T.C., Pitkeathly M., Radford S.E. Responsive gels formed by the spontaneous self-assembly of peptides into polymeric beta-sheet tapes. Nature. 386:1997;259-262.
27. Mayo K.H., Ilyina E., Park H. A recipe for designing water-soluble, beta-sheet-forming peptides. Protein Sci. 5:1996;1301-1315.
28. Jensen P.E. Antigen unfolding and disulfide reduction in antigen presenting cells. Semin. Immunol. 7:1995;347-353.
29. Reid P.A., Watts C. Cycling of cell-surface MHC glycoproteins through primaquine-sensitive intracellular compartments. Nature. 346:1990;655-657.
30. Dimarchi R.D., Tam J.P., Kent S.B., Merrifield R.B. Weak acid-catalyzed pyrrolidone carboxylic acid formation from glutamine during solid phase peptide synthesis. Minimization by rapid coupling. Int. J. Pept. Protein Res. 19:1982;88-93.
31. Bennett S.R., Carbone F.R., Karamalis F., Miller J.F., Heath W.R. Induction of a CD8+ cytotoxic T-lymphocyte response by cross-priming requires cognate CD4+ T-cell help. J. Exp. Med. 186:1997;65-70.
32. Shirai M., Chen M., Arichi T., Masaki T., Nishioka M., Newman M., Nakazawa T., Feinstone S.M., Berzofsky J.A. Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T-lymphocytes (CTL) with CTL epitope peptide vaccines. J. Infect. Dis. 173:1996;24-31.
33. Sauzet J.P., Gras-Masse H., Guillet J.G., Gomard E. Influence of strong CD4 epitope on long-term virus-specific cytotoxic T-cell responses induced in vivo with peptides. Int. Immunol. 8:1996;457-465.
34. Ostankovitch M., Le Gal F.A., Connan F., Chassin D., Choppin J., Guillet J.G. Generation of Melan-A/MART-1-specific CD8+ cytotoxic T-lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T-lymphocyte induction in vitro. Int. J. Cancer. 72:1997;987-994.
35. Sutter R.W. Adverse reactions to tetanus toxoid. JAMA. 271:1994;1629.
36. Ravn P., Boesen H., Pedersen B.K., Andersen P. Human T-cell responses induced by vaccination with Mycobacterium bovis bacillus Calmette-Guerin. J. Immunol. 158:1997;1949-1955.
37. Ahmed R., Gray D. Immunological memory and protective immunity: understanding their relation. Science. 272:1996;54-60.
38. Matloubian M., Concepcion R.J., Ahmed R. CD4+ T-cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:1994;8056-8063.
39. Lalvani A., Brookes R., Hambleton S., Britton W.J., Hill A.V., McMichael A.J. Rapid effector function in CD8+ memory T-cells. J. Exp. Med. 186:1997;859-865.
40. Thomson S.A., Sherritt M.A., Medveczky J., Elliott S.L., Moss D.J., Fernando G.J., Brown L.E., Suhrbier A. Delivery of multiple CD8 cytotoxic T-cell epitopes by DNA vaccination. J. Immunol. 160:1998;1717-1723.
41. Thomson S.A., Elliott S.L., Sherritt M.A., Sproat K.W., Coupar B.E., Scalzo A.A., Forbes C.A., Ladhams A.M., Mo X.Y., Tripp R.A., Doherty P.C., Moss D.J., Suhrbier A. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T-cell epitopes. J. Immunol. 157:1996;822-826.
42. Sauzet J.P., Deprez B., Martinon F., Guillet J.G., Gras-Masse H., Gomard E. Long-lasting anti-viral cytotoxic T-lymphocytes induced in vivo with chimeric-multirestricted lipopeptides. Vaccine. 13:1995;1339-1345.
43. Tsang K.Y., Zaremba S., Nieroda C.A., Zhu M.Z., Hamilton J.M., Schlom J. Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 87:1995;982-990.
44. Cox J.C., Coulter A.R. Adjuvants: a classification and review of their modes of action. Vaccine. 15:1997;248-256.
45. Fujii N., Sasaki T., Funakoshi S., Irie H., Yajima H. Studies on peptides. Convenient procedure for the preparation of methione sulphoxide derivatives. Chem. Pharm. Bull. 26:1978;650-655.
46. Stryhn A., Pedersen L.O., Romme T., Olsen A.C., Nissen M.H., Thorpe C.J., Buus S. pH dependence of MHC class I-restricted peptide presentation. J. Immunol. 156:1996;4191-4197.
47. Hsu Y.R., Narhi L.O., Spahr C., Langley K.E., Lu H.S. In vitro methionine oxidation of Escherichia coli-derived human stem cell factor: effects on the molecular structure, biological activity, and dimerization. Protein Sci. 5:1996;1165-1173.